Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate

Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.31) by 96.77 percent. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.